

Date of preparation: 17 May 2024

Issuer's abbreviated name: SYNEKTIK SA

Current report: 26/2024 ESPI

Subject: Information on the conclusion of a significant agreement on the sale of a robotic system

Legal basis: Article 17 sect. of MAR – inside information

Body of the report:

Time of publication: 1:31 p.m.

The Management Board of Synektik SA (Company) reports that the Company has learned that its subsidiary doing business as SYNEKTIK Czech Republic, s.r.o. with its registered office in Prague, Czech Republic concluded significant agreements with the Havířov Hospital (Nemocnice Havířov) with its registered office in Dělnická 1132/24, 73601 Havířov, Czech Republic (Hospital).

These agreements pertain to the sale, delivery, installation and commissioning of the da Vinci minimally invasive surgery robotic system for the Hospital, personnel training, warranty maintenance care, regular supply of consumable materials for the robotic system and post-warranty maintenance care for 8 years.

These agreements were concluded as a result of the procedure conducted in accordance with Czech public procurement law, and their total maximum net value is USD 4,283,942.44.

The delivery of the robotic system to the Hospital will take place within a term of up to 8 weeks from the date when the Hospital conveys the request to make delivery. The warranty period for system delivery is 24 months from signing the final acceptance report. The other clauses do not deviate from the standards generally used in contracts of this type.

The signing of these agreements has been deemed to be significant by the Management Board of Synektik SA since their combined maximum net value exceeds 5% of the equity of the Synektik Group disclosed in the last periodic report, meaning that it surpasses the level prescribed internally in the



Company in its individual reporting standards. The proceeds generated by executing this project will affect the sales results in the 2023 financial year lasting from 1 October 2023 to 30 September 2024, as well as in subsequent financial years from 2024 to 2033.

Persons representing the Issuer:

Cezary Kozanecki – President of the Management Board